FDA Commissioner nominee Heidi Overton deflected multiple questions about her willingness to stand up to pressure from ...

The US regulatory agency has just started a priority review of Imfinzi (durvalumab), in combination with Pfizer and ...

Orca Bio's manufacturing facility in Sacramento, California. Orca Bio has become a commercial-stage company with the FDA approval of Tregzi, a cell-based immunotherapy designed to prevent graft-versus ...

These specialised professionals work alongside sites to uncover recruitment challenges early, using clinical expertise and ...

Takeda's $300 million wager on Protagonist Therapeutics' rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off. The first phase 3 trial of the injectable hepcidin mimetic, ...

The Swiss pharma group has just reported topline results from the phase 3 IMAgINATION study of Factor B inhibitor sefaxersen ...

AI-powered drug discovery companies Enveda Biosciences and Basecamp Research have completed impressive funding rounds – worth ...

Dazodalibep is one of the assets included in Amgen's near-$28 billion takeover of Horizon Pharma in 2023, which also gave it ...

The FDA has approved Eli Lilly's once-weekly basal insulin product Onswik for adults with type 2 diabetes, setting up a market tussle with Novo over its recently launched Awiqli. Onswik (insulin ...

Roche has revealed new phase 2 data with enicepatide (formerly CT-388), its potential rival to Eli Lilly's dual GIP/GLP-1 ...

The FDA's experts looked at data from NHS-Galleri, as well as the US and Canadian PATHFINDER 2 study, which enrolled more than 35,000 subjects and showed that the test was able to increase cancer ...